Australian OEM Firm Axxin Readying Readers for Partners' Isothermal Amplification MDx Tests | GenomeWeb

This article has been corrected from a previous version that stated that Axxin disclosed in January that it is developing the NAT analyzer and iNAT platforms. In fact, Alere disclosed that it is developing these platforms.

Anticipating a market influx of molecular tests based on isothermal nucleic acid amplification technologies, Australian OEM firm Axxin is developing a pair of instrument platforms — one for the benchtop and one for the point of care — designed to rapidly and inexpensively perform such tests and provide actionable results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.